Biotricity

Biotricity, Inc. is a medical technology company, which is focused on biometric data monitoring solutions. It is also involved in delivering remote monitoring solutions to the medical, healthcare, and consumer markets, with a focus on diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. The firm’s FDA-approved Bioflux MCT technology is comprised of monitoring device and software components, which are made available to the market to assess, establish and develop sales processes, and market dynamics. The company was founded by Waqaas Al-Siddiq and Peter McGoldrick on August 29, 2012 and is headquartered in Redwood City, CA.

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Biotricity achieves positive EBITDA in Q2 2025, poised for growth

Biotricity's Q2 2025 performance showcased positive EBITDA, revenue growth, and operational improvements.
The company's strategic strengths lie in expanding capabilities, forming partnerships, and meeting market demand.
Challenges include sustaining profitability, reducing expenses, and navigating competitive pressures.
Opportunities for Biotricity include growth through partnerships, revenue model optimization, and market expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Biotricity, Inc. is a medical technology company, which engages in biometric data monitoring solutions. It operates through the following segments: Resting (Non-stress) ECG Systems, Stress ECG Systems, and Holter Monitoring Systems. The company was founded by Waqaas Al-Siddiq and Peter McGoldrick on August 29, 2012 and is headquartered in Redwood City, CA.

Closes $15 Million Underwritten Public Offering REDWOOD CITY, CA / ACCESSWIRE / August 30, 2021 /  Biotricity, Inc. (NASDAQ: BTCY), a medical diagnostic and consumer healthcare technology company, today announced the closing of an underwritten public offering of 5,000,000 shares of common stock of the Company for total gross proceeds to the Company of approximately $15 million. The offering was priced at $3.00 per share.

Biotricity Completes Nasdaq Listing.

Closes $15 Million Underwritten Public Offering REDWOOD CITY, CA / ACCESSWIRE / August 30, 2021 / Biotricity, Inc. (NASDAQ:BTCY), a medical diagnostic and consumer healthcare technology company, today announced the closing of an underwritten public offering of 5,000,000 shares of common stock of the Company for total gross proceeds to the Company of approximately $15 million. The offering was priced at $3.00 per share.

Biotricity Completes Nasdaq Listing

REDWOOD CITY, CA / ACCESSWIRE / August 26, 2021 /  Biotricity, Inc. (OTCQB: BTCY), a medical diagnostic and consumer healthcare technology company, today announced the pricing of an underwritten public offering of 5,000,000 shares of common stock of the Company, at a price of $3.00 per share for total gross proceeds to the Company of approximately $15 million. In addition, the Company has granted the underwriter of the offering a 30-day option to purchase an additional 750,000 shares of common stock at the public offering price, less underwriting discounts and commissions.

Biotricity Prices $15 Million Underwritten Public Offering of Common Stock and Listing on the Nasdaq Capital Market

REDWOOD CITY, CA / ACCESSWIRE / August 25, 2021 / Biotricity, Inc. (OTCQB:BTCY), a medical diagnostic and consumer healthcare technology company, today announced that it intends to offer shares of its common stock for sale in an underwritten public offering. In addition, the Company expects to grant the underwriter of the offering a 30-day option to purchase additional shares of common stock at the public offering price, less underwriting discounts and commissions.

Biotricity Announces Proposed Underwritten Public Offering of Common Stock in Connection with Expected Nasdaq Listing

Biotricity, Inc. (BTCY) CEO Waqaas Al-Siddiq on Q1 2022 Results - Earnings Call Transcript

REDWOOD CITY, CA / ACCESSWIRE / August 16, 2021 / Biotricity, Inc. (OTCQB:BTCY), a medical diagnostic and consumer healthcare technology company, is pleased to provide financial results for its fiscal 2022 first quarter, which ended June 30, 2021. Full financial results will be posted on EDGAR later today.

Biotricity Reports 290% Revenue Growth Year Over Year in Record First Quarter

REDWOOD CITY, CA / ACCESSWIRE / August 12, 2021 / Biotricity, Inc. (OTCQB:BTCY), a medical diagnostic and consumer healthcare technology company, today announced that it will release its financial results for the first quarter of fiscal 2022, ended June 30, 2021, on Monday, August 16, 2021, after the close of the market. Biotricity management will host a conference call and live webcast on August 16, 2021 at 1:30 p.m.

Biotricity to Report First Quarter Fiscal 2022 Financial Results on August 16, 2021

A new study revealed that 44% of older millennials that will soon hit 40 suffer at least one chronic health condition that takes a toll, both financially and emotionally — an alarming number compared to previous generations Chronic care is not only growing and creating considerable demand on health systems; it is also becoming alarmingly costly for these patients.

Innovative Company Biotricity is Providing Solutions for Chronic Diseases

Cannabix Technologies Inc.

Soligenix

Reddit traders aren't just focused on short squeezes. Here are seven ultra-risky Reddit penny stocks that have caught their attention.

7 Reddit Penny Stocks to Bet On if You Have $100 to Gamble

Fiscal Q1-22 to be the 9th quarter of growth and biggest quarter to date REDWOOD CITY, CA / ACCESSWIRE / July 7, 2021 / Biotricity, Inc. (OTCQB:BTCY), a medical diagnostic and consumer healthcare technology company, today announced preliminary revenue results guidance for its 2022 fiscal first quarter, ended June 30, 2021. In its fiscal first quarter, Biotricity continued its revenue acceleration trend following its record 2021 fiscal fourth quarter and full year results.

Biotricity's 2021 Fiscal Fourth Quarter Growth Trend Continues into Fiscal 2022

For fiscal 2021, management is noting the following highlights: Q4 revenue of $1.2 million represented the 8th consecutive quarter of triple-digit YoY growth

Biotricity Reports Record Quarterly and Annual Revenue for Fiscal 2021

Biotricity, Inc. (BTCY) CEO Waqaas Al-Siddiq on Q4 2021 Results - Earnings Call Transcript

REDWOOD CITY, CA / ACCESSWIRE / June 9, 2021 / Biotricity, Inc. (OTCQB:BTCY), a medical diagnostic and consumer healthcare technology company, today announced that it will release its financial results for the fourth quarter and full fiscal year 2021, ended March 31, 2021, on Tuesday, June 15, 2021, after the close of the market. Biotricity management will host a conference call and live webcast for analysts and investors on June 15, 2021 at 1:30 p.m.

Biotricity to Report Fourth Quarter Fiscal 2021 and Financial Results on June 15, 2021

REDWOOD CITY, CA / ACCESSWIRE / June 1, 2021 / Biotricity Inc. (OTCQB:BTCY) ("Biotricity" or the "Company"), a medical diagnostic and consumer healthcare technology company, announced today that its CEO Waqaas Al-Siddiq will be presenting virtually at the upcoming LD Micro Invitational XI event on Tuesday, June 8, 2021, at 11:30 a.m. EDT (8:30 a.m.

Biotricity to Present at 2021 LD Micro Invitational XI

REDWOOD CITY, CA / ACCESSWIRE / May 25, 2021 / Biotricity, Inc. (OTCQB:BTCY) ("Biotricity" or the "Company"), a medical diagnostic and consumer healthcare technology company, is pleased to announce that it has begun executing on its strategy towards an uplist to a National Exchange in 2021. Waqaas Al-Siddiq, CEO of Biotricity previously mentioned this as a top priority for 2021.

Biotricity Announces 2021 Uplisting Strategy to Major Exchange

BTCY continues to win new business at a rapid pace, with current quarterly revenue likely to be double revenue reported just two quarters ago, well ahead of management's past guidance. Reduced reimbursement rates for extended holter have no impact on BTCY, unlike the negative impact it has for competitors.

Biotricity: Equipping Doctors,  Empowering Patients, Enriching Shareholders

Biotricity Inc (OTC: BTCY) has a multi-billion dollar target addressable market, which should expand as an ecosystem is created for solutions to chronic conditions, according to Maxim Group. The Biotricity Analyst: Allen Klee initiated coverage of Biotricity with a Buy rating and a price target of $6.

Maxim Group Is Bullish About Biotricity Generating Over 100% Revenue Growth

REDWOOD CITY, CA / ACCESSWIRE / May 4, 2021 / Biotricity, Inc. (OTCQB:BTCY) ("Biotricity" or the "Company"), a medical diagnostic and consumer healthcare technology company, is pleased to announce that it's Biotres device is a finalist in Fast Company's 2021 World Changing Ideas. The World Changing Ideas Awards is a yearly award that honors businesses and projects that are committed to pursuing innovation to solve global issues.

Biotricity Selected as Finalist in Fast Company's 2021 World Changing Ideas Awards

Unaudited Financial Results Include Revenue Growth of 133% REDWOOD CITY, CA / ACCESSWIRE / April 14, 2021 / Biotricity, Inc. (OTCQB:BTCY) ("Biotricity" or the "Company"), a medical diagnostic and consumer healthcare technology company, is pleased to announce another record year in its revenue growth based on its unaudited, preliminary financial results for its fiscal year ended March 31, 2021. Full audited financial results will be filed with the SEC on EDGAR prior to June 14, 2021.

Biotricity to Report Record Revenue Results for Fiscal 2021

AUSTIN, Texas, March 16, 2021 (GLOBE NEWSWIRE) -- SmallCapVoice.com Inc. (“SCV”) announces the availability of a new interview with Dr. Waqaas Al-Siddiq, CEO of Biotricity Inc. (OTCQB: BTCY) (“the Company”), a modern medical technology company delivering disruptive solutions to the multi-billion-dollar cardiac monitoring and diagnostic market.

Biotricity CEO Discusses Calculated Growth Strategy in Audio Interview with SmallCapVoice.com

REDWOOD CITY, CA / ACCESSWIRE / March 15, 2021 / Biotricity, Inc. (OTCQB:BTCY) ("Biotricity" or the "Company"), a medical diagnostic and consumer healthcare technology company, is pleased to announce that CEO Waqaas Al-Siddiq will present at Maxim Group's Inaugural Emerging Growth Virtual Conference to be held March 17-19, 2021. Dr. Al-Siddiq will participate in a Healthcare IT panel on Thursday March 18th from 3:30-4:30 PM Eastern Time (12:30-1:30 PM Pacific) and a fireside chat with Maxim analyst Allen Klee on Friday March 19th, from 11:30-12:00 AM Eastern Time (8:30-9:00 AM Pacific).

Biotricity, Inc. to Present at Maxim Group's 2021 Inaugural Emerging Growth Virtual Conference

BTCY is a possible industry disruptor with triple-digit growth rates, but few investors know about them. The business approach of BTCY benefits both physicians and patients while lowering overall medical expenses.

Biotricity: Poised For Disruptive And Explosive Growth

Biotricity, Inc. (BTCY) CEO Waqaas Al-Siddiq on Q3 2021 Results - Earnings Call Transcript

REDWOOD CITY, Calif., Feb. 08, 2021 (GLOBE NEWSWIRE) -- ﻿﻿ Biotricity, Inc. (OTCQB:BTCY), a medical diagnostic and consumer healthcare technology company, today announced that it will discuss the highlights of its financial results for the third quarter of fiscal 2021, ended December 31, 2020, on Thursday, February 11, 2021, after the close of the market. Full financial results will be filed and available on Tuesday February 16, 2021 .

Biotricity to Report Third Quarter Fiscal 2021 Financial Results on February 11, 2021

REDWOOD CITY, Calif., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY), a medical diagnostic and consumer healthcare technology company, announced today that it has completed a series of closings pursuant to which it sold an aggregate gross proceeds of $9,557,500 of convertible promissory notes to institutional and retail investors in separate offerings. The convertible notes convert into the Company's common stock at a conversion price equal to 75% of the volume weighted average price of the common stock for the five trading days prior to the conversion date. Additionally, the Company will issue the investors in the offering cash warrants based on the amount of promissory notes converted by the investors. The Company believes that conversion of these promissory notes will be instrumental in the Company's path towards a senior market listing.

News for Biotricity Stock (BTCY)